Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 강정옥 | - |
dc.date.accessioned | 2018-03-14T07:42:16Z | - |
dc.date.available | 2018-03-14T07:42:16Z | - |
dc.date.issued | 2014-08 | - |
dc.identifier.citation | Journal of Korean medical science, 2014, 29(8), p1178 ~ 1182 | en_US |
dc.identifier.issn | 1011-8934 | - |
dc.identifier.uri | https://synapse.koreamed.org/DOIx.php?id=10.3346/jkms.2014.29.8.1178 | - |
dc.identifier.uri | http://hdl.handle.net/20.500.11754/46789 | - |
dc.description.abstract | With increase of multi-drug resistant Escherichia coli in community-acquired urinary tractinfections (CA-UTI), other treatment option with a therapeutic efficacy and a low antibioticselective pressure is necessary. In this study, we evaluated in vitro susceptibility of E. coliisolates from CA-UTI to fosfomycin (FM), nitrofurantoin (NI), temocillin (TMO) as well astrimethoprim-sulfamethoxazole (SMX), ciprofloxacin (CIP) and cefepime (FEP). Theminimal inhibitory concentrations were determined by E-test or agar dilution methodaccording to the Clinical and Laboratory Standards Institute guidelines, using 346 E. colicollected in 12 Korean hospitals from March 2010 to February 2011. FM, NI and TMOshowed an excellent susceptibility profile; FM 100% (346/346), TMO 96.8% (335/346),and NI 99.4% (344/346). Conversely, resistance rates of CIP and SMX were 22% (76/346)and 29.2% (101/349), respectively. FEP still retained an activity of 98.5%. In Korea, NI andTMO in addition to FM are a good therapeutic option for uncomplicated CA-UTI, especiallyfor lower UTI. | en_US |
dc.description.sponsorship | This work was supported by a grant of the Korea Healthcare technology R&D Project, Ministry of Health and Welfare, Republic of Korea (A084063). | en_US |
dc.language.iso | en | en_US |
dc.publisher | KOREAN ACAD MEDICAL SCIENCES, 302 75 DONG DU ICHON, DONG YONGSAN KU, SEOUL 140 031, SOUTH KOREA | en_US |
dc.subject | Community-Acquired Infections | en_US |
dc.subject | Urinary Tract | en_US |
dc.subject | Escherichia coli | en_US |
dc.subject | Fosfomycin | en_US |
dc.subject | Nitrofurantoin | en_US |
dc.subject | Temocillin | en_US |
dc.subject | Trimethoprim-Sulfamethoxazole combination | en_US |
dc.subject | Ciprofloxacin | en_US |
dc.subject | Cefepime | en_US |
dc.subject | Minimal Inhibitory Concentration | en_US |
dc.title | Susceptibility of Escherichia coli from Community-Acquired Urinary Tract Infection to Fosfomycin, Nitrofurantoin, and Temocillin in Korea | en_US |
dc.type | Article | en_US |
dc.relation.no | 8 | - |
dc.relation.volume | 29 | - |
dc.identifier.doi | 10.3346/jkms.2014.29.8.1178 | - |
dc.relation.page | 1178-1181 | - |
dc.relation.journal | JOURNAL OF KOREAN MEDICAL SCIENCE | - |
dc.contributor.googleauthor | Seo, Mi-Ran | - |
dc.contributor.googleauthor | Kim, Seong-Jong | - |
dc.contributor.googleauthor | Kim, Yeon-Jae | - |
dc.contributor.googleauthor | Kim, Ji-Eun | - |
dc.contributor.googleauthor | Choi, Tae-Yeal | - |
dc.contributor.googleauthor | Kang, Jung-Oak | - |
dc.contributor.googleauthor | Wie, Seong-Heon | - |
dc.contributor.googleauthor | Ki, Mo-Ran | - |
dc.contributor.googleauthor | Cho, Young-Kyun | - |
dc.contributor.googleauthor | Lim, Seung-Kwan | - |
dc.relation.code | 2014033608 | - |
dc.sector.campus | S | - |
dc.sector.daehak | COLLEGE OF MEDICINE[S] | - |
dc.sector.department | DEPARTMENT OF MEDICINE | - |
dc.identifier.pid | jokang | - |
dc.identifier.researcherID | 55915514100 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.